FIELD: pharmaceuticals; medicine.
SUBSTANCE: object 1 is a method for obtaining a pharmaceutical composition in a solid dosage form by moisture-activated granulation followed by tableting, containing 1 mg of hexamethylenediamide bis-(N-monosuccinyl-L-seryl-L-lysine) and 93 mg of filler - a mixture of microcrystalline cellulose and lactose, 5 mg of a binder - a copolymer of polyvinyl alcohol and polyethylene glycol, and 1 mg of a glidant - magnesium stearate. Object 2 - a method for obtaining a pharmaceutical composition in a solid dosage form by direct compression followed by tableting, containing 1 mg of hexamethylenediamide bis-(N-monosuccinyl-L-seryl-L-lysine), 93 mg of a mixture of microcrystalline cellulose 102 and anhydrous lactose or aqueous lactose , spray dried, 5 mg polyvinyl alcohol-polyethylene glycol copolymer and 1 mg magnesium stearate.
EFFECT: technical result consists in optimizing the method for obtaining a tablet mass of a pharmaceutical composition and improving the pharmaceutical and technological properties of the finished dosage form containing bis-(N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide.
4 cl, 5 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION BASED ON BIS-(N-MONOSUCCINYL-L-SERYL-L-LYSINE) HEXAMETHYLENEDIAMIDE (GSB-106) | 2018 |
|
RU2697254C1 |
| PHARMACEUTICAL COMPOSITION OF NEUROPROTECTIVE ACTION FOR ORAL ADMINISTRATION BASED ON HEXAMETHYLENE AMIDE BIS-(N-MONOSUCCINYL-1-GLUTAMYL-L-LYSINE) (VERSIONS), MADE IN FORM OF A TABLET DISPERSIBLE IN THE ORAL CAVITY | 2018 |
|
RU2740754C1 |
| PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE WITH ANTIPSYCHOTIC ACTIVITY AND SYNTHESIS METHODS THEREOF | 2012 |
|
RU2584653C2 |
| PHARMACEUTICAL COMPOSITION OF NEUROPROTECTIVE ACTION FOR PARENTERAL APPLICATION ON BASIS OF HEXAMETHYLENEDIAMINE BIS-(N-MONOSUCCINYL-L-GLUTAMIL-L-LYSINE) IN LYOPHILIZED DOSAGE FORM | 2017 |
|
RU2678203C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING CEREBROVASCULAR DISORDERS AND METHODS FOR PREPARING THEM | 2012 |
|
RU2559776C2 |
| PHARMACEUTICAL COMPOSITION OF N-(6-PHENYLHEXANOYL)GLYCYL-L-TRYPTOPHAN AMIDE IN SOLID DOSAGE FORM | 2013 |
|
RU2602742C2 |
| "NOOPEPT"-BASE PHARMACEUTICAL COMPOSITION | 2004 |
|
RU2289422C2 |
| AFOBASOL-BASE PHARMACEUTICAL COMPOSITION | 2004 |
|
RU2289403C2 |
| PROLONGED PHARMACEUTICAL COMPOSITION DRUG FORM AND METHOD OF ITS PRODUCTION (VERSIONS) | 2009 |
|
RU2435584C2 |
| LOW-MOLECULAR MIMETIC BDNF AS AN AGENT FOR TREATING OPIOID DEPENDENCE | 2019 |
|
RU2707301C1 |
